ArticleApplied biochemistry and biotechnology2025
Upregulated PCSK9 Level Contributes to Human Pulmonary Microvascular Endothelial Cell Apoptosis in Cigarette Smoke Extract-Induced COPD Models Through TLR4/NF-kappaB Pathway Activation.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis, orchestrated by GPX4 downregulation, serves as a critical mediator of neutrophil extracellular trap-driven pathology in hypoxic pulmonary edema.Apoptosis : an international journal on programmed cell death · 2026Article
- Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in PediatricInternational journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is persistent and can result in irreversible alveolar collapse and increase the risk of cardiovascular disease. PCSK9 belongs to the pro-protein convertase family and is capable of modulating cholesterol metabolism and low-density lipoprotein (LDL). PCSK9 is associated with endothelial dysfunction and its suppression is conducive to vascular function. The aim of this study was to explore PCSK9 expression in the lung tissues of patients with COPD and investigate the regulation of PCSK9 in cigarette smoke extract (CSE)-exposed human pulmonary microvascular endothelial cells (HPMECs) and an in vivo cigarette smoke (CS)-exposed mouse model. PCSK9 is drastically upregulated in the lung tissues of patients with COPD relative to those of individuals who have never smoked. PCSK9 expression in HPMECs and the CS-exposed mouse model was found to increase. Functional assays demonstrated that PCSK9 silencing decreased CS-induced lung injury and neutrophil and macrophage infiltration. PCSK9 silencing also abolished CSE-induced apoptosis by upregulating Bcl-2 and downregulating Bax expression in COPD mice and cell models. PCSK9 silencing alleviated the inflammatory response in the BALF of CS-exposed mice and CSE-treated HPMECs. The protein expression of P65, NLRP3, ASC, TLR4, p-P65, MyD88, and caspase-1 in mouse BALF and HPMECs was inhibited after PCSK9 knockdown. Collectively, these observations indicate the important role of PCSK9 in COPD progression and present promising treatment targets for COPD.
Indexed as
Identifiers
40676468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.